Multiple myeloma trials in United States

In United States 297 Also abroad 703

297 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Early phase 1Not yet taking people in United States
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Where
New York
Age
18 years and over
People
22
Run by
Shambavi Richard
See details and how to joinNCT07727668
Phase 3Not yet taking people in United States
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Aurora, Boston, Cerritos, Chapel Hill, Chicago, Cleveland, Durham, Grand Rapids, Houston, Los Angeles, Madison, Marietta, Nashville, New York, Portland, Richmond, Rochester, Salt Lake City, Tucson, Washington D.C., Weston, Winston-Salem
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 4Taking people
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Where
Atlanta
Age
18 years and over
People
94
Run by
Emory University
See details and how to joinNCT07101445
Phase 2Taking people
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Where
Palo Alto
Age
18 years and over
People
20
Run by
Stanford University
See details and how to joinNCT06461988
Phase 2Taking people
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Where
Boston, Denver, Portland
Age
18 years and over
People
52
Run by
Irene Ghobrial, MD
See details and how to joinNCT05469893
Phase 1Taking people
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Atlanta, Birmingham, Boston, Buffalo, Duarte, Hackensack, Houston, Jacksonville, Nashville, New York, Omaha, Phoenix, Pittsburgh, Rochester
Age
18 years and over
People
187 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06121843
Phase 1/2Taking people
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Where
Boston, Chapel Hill, Denver, Durham, Gilbert, Hackensack, Los Angeles, Madison, Nashville, New York, Omaha, Rochester, Seattle
Age
18 years and over
People
300 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT02343042
Phase 2Taking people
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Where
Jacksonville
Age
18 years and over
People
62
Run by
Mayo Clinic
See details and how to joinNCT05847569
No phaseTaking people
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Where
St Louis
Age
18 years and over
People
990
Run by
Washington University School of Medicine
See details and how to joinNCT06340646
Phase 2Taking people
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Where
Orange
Age
18 years and over
People
75
Run by
University of California, Irvine
See details and how to joinNCT06580002
No phaseTaking people
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Where
Charlotte
Age
30 years and over
People
1,665
Run by
Wake Forest University Health Sciences
See details and how to joinNCT06644625
No phaseTaking people
Pre-malignant States to Hematologic Malignancies in Firefighters
Where
Charlotte
Age
40 years to 49 years
People
300
Run by
Wake Forest University Health Sciences
See details and how to joinNCT06870760
Phase 1Taking people
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Where
St Louis
Age
18 years and over
People
25
Run by
Washington University School of Medicine
See details and how to joinNCT06185751
Phase 2Taking people
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Where
Ann Arbor, Baltimore, Boston, New York, Philadelphia, Seattle, Stony Brook
Age
18 years and over
People
116 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00
No phaseTaking people
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Where
Akron, Amarillo, Ann Arbor, Atlanta, Augusta, Aurora, Baltimore, Beech Grove, Bethesda, Birmingham, Boston, Brandywine, Buffalo, Chapel Hill, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Denver, Detroit, Duarte, Durham, Fort Sam Houston, Fort Worth, Gainesville, Gilbert, Glendale, Grand Rapids, Hackensack, Hershey, Honolulu, Houston, Indianapolis, Iowa City, Jackson, Jacksonville, Kansas City, La Jolla, Lake Sucess, Little Rock, Loma Linda, Los Angeles, Louisville, Lubbock, Madison, Maywood, Memphis, Miami, Milwaukee, Morgantown, Nashville, New Brunswick, New Haven, New Hyde, New Orleans, New York, Oakland, Oklahoma City, Omaha, Orange, Orlando, Park Ridge, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Richmond, Rochester, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, Seattle, Sioux Falls, Stanford, St Louis, Stony Brook, St. Petersburg, Tampa, The Bronx, Tucson, Washington D.C., Westwood, Winston-Salem, Worcester, Zion
People
99,999
Run by
Center for International Blood and Marrow Transplant Research
See details and how to joinNCT01351545
Phase 2Taking people
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Where
Basking Ridge, Boston, Chapel Hill, Commack, Harrison, Middletown, Montvale, New York, Uniondale
Age
18 years and over
People
20
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT06083922
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Ann Arbor, Austin, Coral Gables, Deerfield Beach, Detroit, Fort Collins, Greeley, Irvine, Longmont, Loveland, Miami, Orange
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
Phase 1Taking people
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Where
Rochester, Scottsdale
Age
18 years and over
People
21
Run by
Mayo Clinic
See details and how to joinNCT06508463
No phaseTaking people
Halt Aging in Survivors of Blood Cancers
Where
Omaha
Age
50 years and over
People
180
Run by
University of Nebraska
See details and how to joinNCT07292272
Phase 1Not yet taking people in United States
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Where
Cleveland
Age
18 years to 75 years
People
27
Run by
Luminary Therapeutics
See details and how to joinNCT07679919
No phaseTaking people
Registry of Older Patients With Cancer
Where
Boone, Chapel Hill, Greenville, Hendersonville, Morehead City, New Bern, Raleigh
Age
65 years and over
People
3,000
Run by
UNC Lineberger Comprehensive Cancer Center
See details and how to joinNCT01137825
No phaseTaking people
Integrated Cancer Repository for Cancer Research
Where
Aitkin, Alliance, Aurora, Bozeman, Brainerd, Canton, Council Bluffs, Daytona Beach, DeLand, Duluth, Fargo, Fayetteville, Fergus Falls, Fort Wayne, Glens Falls, Green Bay, Greenwood Village, Hastings, Holyoke, Kansas City, Liberty, Manchester, Minot, Norfolk, North Kansas City, North Platte, Omaha, Orange City, Overland Park, Palm Coast, Randallstown, Saint Joseph, Tallahassee, Utica, Waterloo, Westminster, Yorkville
Age
19 years to 110 years
People
999,999
Run by
University of Nebraska
See details and how to joinNCT02012699
Phase 2Taking people
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Where
Detroit, Lansing
Age
18 years and over
People
60
Run by
Barbara Ann Karmanos Cancer Institute
See details and how to joinNCT06107738
Phase 2Taking people
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Where
Minneapolis
Age
Up to 60 years
People
300
Run by
Masonic Cancer Center, University of Minnesota
See details and how to joinNCT03314974
Phase 1/2Taking people
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Where
Rochester
Age
18 years and over
People
37
Run by
Mayo Clinic
See details and how to joinNCT06785415